Pietro Ravani1, Isabella Pisani2, Monica Bodria3, Gianluca Caridi3, Maria Ludovica Degl'Innocenti3, Gian Marco Ghiggeri4. 1. Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. 2. Division of Nephrology, School of Nephrology, Department of Medicine and Surgery, University of Parma, Parma, Italy. 3. Laboratory of Molecular Nephrology and Division of Nephrology and Transplantation, IRCCS Istituto Giannina Gaslini, Largo G. Gaslini 5, Genoa, Italy. 4. Laboratory of Molecular Nephrology and Division of Nephrology and Transplantation, IRCCS Istituto Giannina Gaslini, Largo G. Gaslini 5, Genoa, Italy. gmarcoghiggeri@gaslini.org.
Abstract
BACKGROUND:Children with multidrug-resistant nephrotic syndrome (MRNS) are exposed to drug toxicity (steroids/calcineurin inhibitors (CNI)/mycophenolate mofetil (MMF)) and have an increased risk of kidney disease progression. In small case series, the fully humanized anti-CD20 antibody ofatumumab (OFA) induced remission in children with MRNS when at high dose (10,300 mg/1.73 m2) and partial remission at standard dose (1000 mg/1.73 m2). METHODS: This double-blind randomized placebo-controlled trial tested the efficacy of single infusion OFA in children with proven MRNS and initial chronic renal failure (eGFR [median/range] 119/38-155 ml/min/1.73 m2 in Placebo arm vs. 65/19-103 ml/min/1.73 m2 Intervention). Children who had been resistant to a combination of CNI and steroids, with or without MMF orrituximab, were randomized to receive single infusion OFA (1500 mg/1.73 m2) (Intervention arm) or normal saline (Placebo arm). We assessed complete or partial remission of proteinuria after 3 months (primary outcome), and after 6 and 12 months (secondary outcomes), as well as progression to end-stage kidney disease. RESULTS:After 13 of the planned 50 children (25%) were randomized, the data safety and monitoring board recommended study termination for futility. All 13 children remained nephrotic. Renal function worsened in 5 children (2 in Intervention arm, 3 in Placebo arm) who required renal replacement therapy during the study period. Circulating CD20 was reduced following OFA infusion and remained low for > 3 months. CONCLUSIONS:OFA given in one single infusion of 1500 mg/1.73 m2 doses does not induce remission in MRNS. Regimens based on higher OFA doses should be tested in clinical trials. TRIAL REGISTRATION: https://clinicaltrials.gov: NCT02394106.
RCT Entities:
BACKGROUND:Children with multidrug-resistant nephrotic syndrome (MRNS) are exposed to drug toxicity (steroids/calcineurin inhibitors (CNI)/mycophenolate mofetil (MMF)) and have an increased risk of kidney disease progression. In small case series, the fully humanized anti-CD20 antibody ofatumumab (OFA) induced remission in children with MRNS when at high dose (10,300 mg/1.73 m2) and partial remission at standard dose (1000 mg/1.73 m2). METHODS: This double-blind randomized placebo-controlled trial tested the efficacy of single infusion OFA in children with proven MRNS and initial chronic renal failure (eGFR [median/range] 119/38-155 ml/min/1.73 m2 in Placebo arm vs. 65/19-103 ml/min/1.73 m2 Intervention). Children who had been resistant to a combination of CNI and steroids, with or without MMF or rituximab, were randomized to receive single infusion OFA (1500 mg/1.73 m2) (Intervention arm) or normal saline (Placebo arm). We assessed complete or partial remission of proteinuria after 3 months (primary outcome), and after 6 and 12 months (secondary outcomes), as well as progression to end-stage kidney disease. RESULTS: After 13 of the planned 50 children (25%) were randomized, the data safety and monitoring board recommended study termination for futility. All 13 children remained nephrotic. Renal function worsened in 5 children (2 in Intervention arm, 3 in Placebo arm) who required renal replacement therapy during the study period. Circulating CD20 was reduced following OFA infusion and remained low for > 3 months. CONCLUSIONS:OFA given in one single infusion of 1500 mg/1.73 m2 doses does not induce remission in MRNS. Regimens based on higher OFA doses should be tested in clinical trials. TRIAL REGISTRATION: https://clinicaltrials.gov: NCT02394106.
Authors: Alice Bonanni; Marta Calatroni; Matteo D'Alessandro; Sara Signa; Enrica Bertelli; Michela Cioni; Eddi Di Marco; Roberto Biassoni; Gianluca Caridi; Giulia Ingrasciotta; Roberta Bertelli; Armando Di Donato; Maurizio Bruschi; Alberto Canepa; Giorgio Piaggio; Pietro Ravani; Gian Marco Ghiggeri Journal: Br J Clin Pharmacol Date: 2018-03-25 Impact factor: 4.335
Authors: Alberto Magnasco; Pietro Ravani; Alberto Edefonti; Luisa Murer; Luciana Ghio; Mirco Belingheri; Elisa Benetti; Corrado Murtas; Giovanni Messina; Laura Massella; Maria Gabriella Porcellini; Michela Montagna; Mario Regazzi; Francesco Scolari; Gian Marco Ghiggeri Journal: J Am Soc Nephrol Date: 2012-05-10 Impact factor: 10.121
Authors: Pietro Ravani; Manuela Colucci; Maurizio Bruschi; Marina Vivarelli; Michela Cioni; Armando DiDonato; Paolo Cravedi; Francesca Lugani; Francesca Antonini; Marco Prunotto; Francesco Emma; Andrea Angeletti; Gian Marco Ghiggeri Journal: J Am Soc Nephrol Date: 2021-09-20 Impact factor: 14.978
Authors: Ben C Reynolds; Angela Lamb; Caroline A Jones; Pallavi Yadav; Kay S Tyerman; Colin C Geddes Journal: Pediatr Nephrol Date: 2021-08-12 Impact factor: 3.714